The study demonstrated that weekly intraperitoneal injections of these ASO-loaded T1 nanoparticles at a low dose (0.9 mg·kg−1 per week) led to significant restoration of dystrophin expression in skeletal muscles and the heart of the treated mdx mice, a commonly used model for DMD. This evidence concerns the gene DMD and Duchenne muscular dystrophy.